Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo‐controlled trial

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Hepatology

• Publication date

  1997-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/hep.510250144PMID 8985298
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A preliminary trial of lamivudine for chronic hepatitis B infection.

  1995cited by this paper
• Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells.

  1995cited by this paper
• Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

  1995cited by this paper
• Transplantation of a hepatitis B surface antigen-positive donor liver into a hepatitis B virus-negative recipient.

  1994cited by this paper
• Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

  1993cited by this paper
• Natural history of chronic hepatitis B virus infection: new light on an old story.

  1993cited by this paper
• The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

  1992cited by this paper
• A controlled trial of interferon with or without prednisone priming for chronic hepatitis B.

  1992cited by this paper
• Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication.

  1992cited by this paper
• Effect of recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier children.

  1991cited by this paper
• Hepatitis B: Evolving Epidemiology and Implications for Control

  1991cited by this paper
• Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection.

  1988cited by this paper
• Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children.

  1987cited by this paper

• Expression variation of Akt and cytokines in lamivudine-resistant HBV rare mutation that prematurely truncates the overlapping surface protein.

  2025cites this paper
• Liver Cirrhosis & Hepatocellular Carcinoma in Chronic Hepatitis B: Role of Hepatic Vena Cava Syndrome in the Pathogenesis

  2023cites this paper
• Screening for Hepatitis C Virus Infection in Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

  2020cites this paper
• Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

  2020cites this paper
• Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review

  2020cites this paper
• Analytical Method development and Validation of Lamivudine in Formulation by using Reversed Phase Ultra Performance Liquid Chromatography

  2020cites this paper
• Bayesian Network Meta-Analysis for Assessing Adverse Effects of Anti-hepatitis B Drugs

  2019cites this paper
• Hepatitis B associated Membranoproliferative Glomerulonephritis successfully treated with Entecavir with brief review of literature

  2019cites this paper
• Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B

  2016cites this paper
• RISPR / Cas 9 produces anti-hepatitis B virus effect in hepatoma cells nd transgenic mouse

  2016cites this paper
• Antiviral therapy with nucleotide/nucleoside analogues in chronic hepatitis B: A meta-analysis of prospective randomized trials

  2016cites this paper
• CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse.

  2016cites this paper
• Chronic Hepatitis B Viral Infection

  2015cites this paper
• Lamivudine Resistance and Precore Variants in Iranian Patients With Chronic Hepatitis B: Correlation With Virological and Clinical Features

  2015cites this paper
• Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.

  2015cites this paper
• Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir

  2014cites this paper
• HEPATITIS AND PHYSIOLOGY OF LIVER CELLS-A REVIEW

  2014cites this paper
• Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: Systematic Review to Update the 2004 U.S. Preventive Services Task Force Recommendation

  2014cites this paper
• Screening for Hepatitis B Virus Infection in Adolescents and Adults: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation

  2014influential citation
• Mother‐to‐child transmission of HBV: review of current clinical management and prevention strategies

  2014cites this paper
• Viral Infections in Patients with Hematological Malignancies

  2013cites this paper
• Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment.

  2012cites this paper
• Characteristics of adefovir resistance in patients with or without lamivudine‐resistant hepatitis B virus treated with adefovir: a 4‐year experience

  2011cites this paper
• Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment

  2010cites this paper
• Concordância entre duas técnicas de quantificação do HBVDNA e associações com fibrose hepática em pacientes portadores de infecção crônica pelo vírus B da hepatite HBeAg negativos

  2010cites this paper
• Antiviral Drugs (Other than Antiretrovirals)

  2010cites this paper
• Quantification of lamivudine in human plasma by hydrophilic interaction chromatography-tandem mass spectrometry.

  2010cites this paper
• Lamivudine in Late Pregnancy to Interrupt In Utero Transmission of Hepatitis B Virus: A Systematic Review and Meta-Analysis

  2010cites this paper
• Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance.

  2010cites this paper
• Hepatitis B: Prognosis and Treatment

  2010cites this paper
• Lamivudine for the treatment of HIV

  2010cites this paper
• Evidence Review Group Report commissioned by the NHS R&D HTA Programme on behalf of NICE

  2009cites this paper
• Tratamiento e historia natural de la Hepatitis crónica C en pacientes coinfectados por VIH-1

  2009cites this paper
• Screening for hepatitis B in chemotherapy patients: survey of current oncology practices

  2009cites this paper
• Chronic hepatitis B: interferon – monotherapy or combination with nucleoside analogues?

  2008cites this paper
• Membranous Glomerulonephropathy Associated with Hepatitis B Virus Infection

  2008cites this paper
• Genetic Variability of Hepatitis B virus and Response to Antiviral Therapy

  2008cites this paper
• Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine.

  2008cites this paper
• 16 - Traitement des hépatites virales

  2008cites this paper
• Targeted screening of SiRNA directed HBV polymerase gene for effective inhibition of HBV expression

  2008cites this paper
• Aspects cliniques et épidémiologiques des infections à virus de l'hépatite B en République Centrafricaine

  2008cites this paper
• Effects of antiviral agents and HBV genotypes on intrahepatic covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients.

  2008cites this paper
• Direct detection of lamivudine-resistant hepatitis B virus mutants by a multiplex PCR using dual-priming oligonucleotide primers.

  2008cites this paper
• Current therapy of chronic hepatitis B.

  2007cites this paper
• Antiviral therapy and resistance with hepatitis B virus infection.

  2007cites this paper
• Genotyping and genomic sequencing in clinical practice.

  2007cites this paper
• Fructus schisandrae (Wuweizi)-containing compound inhibits secretion of HBsAg and HBeAg in hepatocellular carcinoma cell line.

  2007cites this paper
• Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine‐resistant hepatitis B virus during adefovir therapy

  2007cites this paper
• Molecular Analysis of Hepatitis B Virus DNA and Mutation Status in Patients Under Lamivudine ((-) 2' 3'-dideoxy-3'-thiacytidine) Therapy

  2007cites this paper
• Viral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis B.

  2007cites this paper
• Management of chronic hepatitis B: consensus guidelines.

  2007cites this paper
• Prolonged Lamivudine Treatment in Patients with Chronic Active Anti-HBe–Positive Hepatitis

  2006cites this paper
• Clinical Implications of Hepatitis B Virus Genotype

  2006cites this paper
• Treatment options in HBV.

  2006cites this paper
• Dynamic changes of HBV DNA in serum and peripheral blood mononuclear cells of chronic hepatitis patients after lamivudine treatment.

  2006cites this paper
• Early detection and quantification of lamivudine-resistant hepatitis B virus mutants by fluorescent biprobe hybridization assay in lamivudine-treated patients

  2006cites this paper
• Extended Lamivudine Treatment in Patients Affected by Chronic Active Anti-Hbe Positive Hepatitis

  2006cites this paper
• Response to long‐term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C

  2006cites this paper
• Fully automated quantitation of hepatitis B virus (HBV) DNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system.

  2006cites this paper
• Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy.

  2006cites this paper
• 397 Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy Hepatitis

  2005cites this paper
• Advances in Molecular Diagnosis of HBV Infection and Drug Resistance

  2005cites this paper
• Character of HBV (hepatitis B virus) polymerase gene rtM204V/I and rtL180M mutation in patients with lamivudine resistance

  2005cites this paper
• Alpha/Beta Interferon Differentially Modulates the Clearance of Cytoplasmic Encapsidated Replication Intermediates and Nuclear Covalently Closed Circular Hepatitis B Virus (HBV) DNA from the Livers of Hepatocyte Nuclear Factor 1α-Null HBV Transgenic Mice

  2005cites this paper
• Establishment of a screening system for selection of siRNA target sites directed against hepatitis B virus surface gene.

  2005cites this paper
• Therapeutic implications of hepatitis B virus genotypes

  2005cites this paper
• Risk factors of intrahepatic recurrence after curative resection of hepatocellular carcinoma.

  2005cites this paper
• Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy

  2005cites this paper
• Virological Response and Incidence of Adefovir Resistance in Lamivudine-Resistant Patients Treated with Adefovir Dipivoxil

  2005cites this paper
• Medikamentöse Therapie der chronischen Hepatitis B

  2005cites this paper
• Inhibition of hepatitis B virus replication by various RNAi constructs and their pharmacodynamic properties.

  2005cites this paper
• Inhibition of Hepatitis B virus gene expression by single and dual small interfering RNA treatment

  2005cites this paper
• Achievements and Challenges in Antiviral Drug Discovery

  2005cites this paper
• Influence of hepatitis B virus genotypes on the response to antiviral therapies.

  2005cites this paper
• Inhibition of hepatitis B virus replication by recombinant small interfering RNAs.

  2005cites this paper
• Emergence of a Novel Mutation in the FLLA Region of Hepatitis B Virus during Lamivudine Therapy

  2005cites this paper
• Character of HBV (hepatitis B virus) polymerase gene rtM204V/I and rtL180M mutation in patients with lamivudine resistance.

  2005cites this paper
• Current treatment and future directions in the management of chronic hepatitis B viral infection.

  2005cites this paper
• Traitement médicamenteux de l'hépatite B chronique

  2005cites this paper
• Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy—A prospective case series

  2005cites this paper
• Therapeutic inhibition of hepatitis B virus surface antigen expression by RNA interference.

  2005cites this paper
• Safety and efficacy of alamifovir in patients with chronic hepatitis B virus infection.

  2004cites this paper
• Studying the treatment of chronic hepatitis B viral infection in special populations.

  2004cites this paper
• Development of Human Antibody Inhibiting RNase H Activity of Polymerase of Hepatitis B Virus Using Phage Display Technique

  2004cites this paper
• A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.

  2004cites this paper
• YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine

  2004cites this paper
• Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients

  2004cites this paper
• Detection of Intrahepatic Hepatitis B Virus DNA and Correlation with Hepatic Necroinflammation and Fibrosis

  2004cites this paper
• Reverse transcriptase activity of hepatitis B virus (HBV) DNA polymerase within core capsid: interaction with deoxynucleoside triphosphates and anti-HBV L-deoxynucleoside analog triphosphates.

  2004cites this paper
• Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy

  2004cites this paper
• Lamivudine Facilitates Optimal Chemotherapy in Hepatitis B Virus-Infected Children with Hematological Malignancies: A Preliminary Report

  2004cites this paper
• Valaciclovir for Chronic Hepatitis B Virus Infection after Lung Transplantation

  2004cites this paper
• Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants.

  2004cites this paper
• The past, present and future of antiviral drug discovery.

  2004cites this paper
• Management of hepatitis B in children.

  2004cites this paper
• Identification of rare polymerase variants of hepatitis B virus using a two‐stage PCR with peptide nucleic acid clamping

  2004cites this paper
• Lamivudine Resistance‐Associated Gene Mutations

  2004cites this paper
• Early detection of hepatitis B drug resistance: implications for patient management

  2003cites this paper
• A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus–related cirrhosis

  2003cites this paper
• Interruption of HBV intrauterine transmission: a clinical study.

  2003cites this paper